Save money and time, get standardized analysis
Analyses from the same vendor for 19 different EU countries
We will help you navigate through the challenges of reimbursement and funding for medical devices and in-vitro diagnostics in Europe
MTRC is a unique provider of Pan-European reimbursement services and products for Med Tech and IVD industry
MTRC is a unique provider of Pan-European reimbursement services and products for Med Tech and IVD industry
Scope
Coding, payment mechanism, reimbursement tariffs, pathway to create or improve reimbursement situation
Countries
19 EU
Availability
Mixed
Scope
Seminars on introduction into market access for medical devices and IVD tests, seminars on reimbursement systems in individual countries
Countries
19 EU
Availability
Off-the-shelf
Scope
Fact-based approach to determine evidence requirements, based on the prevision reimbursement decisions
Countries
Europe
Availability
On demand
Why us?
Pharma approach is put aside
Work with a company truly specialized in medical devices and diagnostics
Getting results instantly (reports) or within 4-8 weeks (services)
Make business decisions quickly
13 out of top-30 companies choose MTRC for reimbursement support
Work with a provider who understands industry’s needs
More than 110 projects accomplished during the last year
Work with a provider who has experience in your field
Team of 15 specialists in 6 countries
Work with a provider with a Pan-European capacity
More than 200 internal instructions and protocols
Be sure about quality of the results
To stay up-to-date, we daily monitor developments of reimbursement systems in Europe
Subscribe to our newsletter to get updates every 2nd week
23 Mar 2020
A syndicated 105-page report includes information on the current administrative framework for health apps, current reimbursement framework, examples of reimbursed apps, the role of health technology assessment, upcoming changes in the reimbursement systems. The report includes analysis in five European countries: Belgium, England, France, Germany, and the Netherlands.
08
Apr 2020
In March 2020, the Nomenclature was updated. The update brought changes regarding the creation of new codes, deletion of codes, modification of existing codes, and reimbursement conditions.
07
Apr 2020
On March 5, 2020, the NHS Innovation Accelerator (NIA) announced the 11 high impact innovations that will enter the national accelerator in 2020. As outlined in the NHS Long Term Plan, the technologies that enter the award-winning NIA provide solutions that help prioritize areas for NHS.
06
Apr 2020
On March 30, 2020, the French High Authority for Health, has published the opinion of the National Commission for the Evaluation of Medical Devices and Health Technologies (CNEDiMTS) regarding the Impella 5.0 device. The clinical added value was graded with level II (important) for the post-cardiotomy cardiogenic shock indication. After the negotiation with CEPS, Impella might be the first short-term VAD to enter add-on reimbursement list LPPR.
03
Apr 2020
The report presents a summary of the reimbursement situation for minimally invasive treatment of prostate cancer in Europe. The following procedures are considered under the scope of analysis: high intensity focused ultrasound (HIFU), cryoablation, focal laser ablation, radiofrequency ablation, microwave thermal ablation of the prostate. Open and laparoscopic radical prostatectomy, as well as external radioation therapy and low-dose-rate barchytherapy, are considered as comparators. The analysis covers procedure coding, payment mechanism, reimbursement tariffs and policy restrictions in 11 EU countries including Austria, Belgium, Denmark, England, France, Germany, Italy, the Netherlands, Norway, Sweden and Switzerland. It is also possible to add analysis in the Czech Republic, Finland, Hungary, Romania, Russia and Turkey.
Our two core services are the provision of off-the-shelf and on-demand reimbursement analysis and the development of reimbursement strategy for medical devices in 19 European countries
| Analysis | |
Reimbursement
|
National fundingWillingness to pay for technology, based on:
|
| Strategy |
Reimbursement strategyPathway to get reimbursement:
|
Check our specific propositions for: Med Tech industry, IVD industry, Investors
Our services cover 19 European countries, including Austria, Belgium, Czech Republic, Denmark, England, Finland, France, Germany, Hungary, Italy, the Netherlands, Norway, Poland, Romania, Russia, Spain, Sweden, Switzerland and Turkey
We provide services for major types of medical technologies
|
Implantable devices |
Interventional procedures |
Non-interventional procedures |
In-vitro diagnostic tests |
Medical aids |
|
Our analytical team has worked on hundreds of reimbursement projects within different clinical and technological areas, including heart valve replacement, minimally invasive and open heart surgery, coronary, cerebral and peripheral stenting, coronary diagnostic and imaging techniques (fractional flow reserve, intravascular ultrasound), coronary, cerebral and peripheral vascular thrombectomy, implantable and extracorporeal ventricular assist devices, clinic- and home-based dialysis, extracorporeal membrane oxygenation, apheresis, obesity surgery, hernia and reconstruction surgery, tissue products and skin reconstruction surgery, negative wound pressure therapy and medical bandages, neurostimulators for different indications, cell therapy, rehabilitation devices, devices for minimally invasive and open spine surgery, embolization procedures, glucose monitoring, use of fusidial markers, radiotherapy, endoscopy and more
|
Confidence in results
We have established numerous procedures and services to ensure the high relevance and precision of our analysis in order to successfully guide your business decisions:
- Standard Operating Procedures and Work Instructions
- Access to official coding and DRG manuals, tariff lists and grouping software
- A team comprised of experienced Clinical Coders with a medical background
- Quick access to health authorities to address uncertainties
- Ongoing research program to get insights from payer and provider interviews
- All reports are reviewed by the CEO before release
Check out our database of the off-the-shelf reimbursement reports for medical technologies in 11 European countries
Released reports:
|
Ongoing reports:
|